Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Axonics

Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2022

Benzinga's Top Ratings Upgrades, Downgrades For October 10, 2022

Analyst Ratings for Axonics

Analyst Ratings for Axonics

Within the last quarter, Axonics (NASDAQ:AXNX) has observed the following analyst ratings:

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022

FDA Approves Axonics' Recharge-Free Sacral Neuromodulation System

Analyst Ratings For Axonics

Axonics (NASDAQ:AXNX) has observed the following analyst ratings within the last quarter:

Axonics: Q4 Earnings Insights

Axonics (NASDAQ:AXNX) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Axonics beat estimated earnings by 8.11%, reporting an EPS of $-0.34 versus an estimate of $-0.37.

inkl

Read news from The Economist, FT, and more,
with one subscription

Organisations

Abbott Laboratories

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play